Miraculins Announces Shares for Debt Settlement
(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 12/29/14 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has entered into a shares for debt agreement with an officer of the Company and a member of the senior management team pursuant to which, and subject to regulatory approval, Miraculins will issue 133,660 of its common shares to said individuals at a deemed price of $0.245 per common share to satisfy $32,746.70 of outstanding amounts owing to them.
All of the shares to be issued will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.12.2014 - 11:30 Uhr
Sprache: Deutsch
News-ID 361622
Anzahl Zeichen: 0
contact information:
Town:
WINNIPEG, MANITOBA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 336 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Miraculins Announces Shares for Debt Settlement"
steht unter der journalistisch-redaktionellen Verantwortung von
Miraculins Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
